Pàgina inicial > Resultats de la cerca: Hematological Oncology
  Consells de cerca
Cerca avançada
Cerca col·leccions:
Ordena'ls per: Mostrar els resultats: Format de visualizació:
Dipòsit Digital de Documents de la UAB 4 registres trobats  La cerca s'ha fet en 0.01 segons. 
1.
10 p, 496.7 KB Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma : IKEMA subgroup analysis / Facon, Thierry (Lille University Hospital) ; Moreau, Philippe (University of Nantes) ; Martin, Thomas G. (University of California San Francisco) ; Spicka, Ivan (Charles University and General Hospital, Prague, Czech Republic) ; Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Koh, Youngil (Seoul National University Hospital, South Korea) ; Lim, Andrew (Austin & Repatriation Medical Center, Heidelberg, Victoria, Australia) ; Mikala, Gabor (South Pest Central Hospital, Budapest, Hungary) ; Rosiñol, Laura (Hospital Clínic i Provincial de Barcelona) ; Yağci, Münci (Gazi University, Ankara, Turkey) ; Cavo, Michele (Bologna University School of Medicine, Italy) ; Yong, Kwee (University College Hospital, London, UK) ; Risse, Marie Laure (Sanofi R&D, Vitry-Sur-Seine, France) ; Asset, Gaëlle (Sanofi R&D, Chilly-Mazarin, France) ; Schwab, Sandrine (Sanofi R&D, Chilly-Mazarin, France) ; Martinez, Gracia (Hospital das Clínicas de São Paulo, Brazil)
In this subgroup analysis of the randomized, Phase 3 IKEMA study (NCT03275285), we evaluated efficacy and safety of the anti-CD38 monoclonal antibody isatuximab (Isa) in combination with carfilzomib-dexamethasone (Isa-Kd) versus Kd in older (≥70 years of age, n = 86) and younger (<70 years, n = 216) patients with relapsed multiple myeloma (MM). [...]
2022 - 10.1002/hon.3038
Hematological Oncology, Vol. 40 Núm. 5 (december 2022) , p. 1020-1029  
Registre complet - Creative Commons
2.
12 p, 600.5 KB A phase 1/2, open-label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma / Carlo-Stella, Carmelo (Humanitas Research Hospital (Itàlia)) ; Zinzani, Pier Luigi (IRCCS Azienda Ospedaliero-Universitaria di Bologna) ; Sureda, Anna (Hospital Universitari de Bellvitge) ; Araújo, Luis (Universitário de Coimbra) ; Casasnovas, Olivier (CHU Dijon Bourgogne) ; Carpio Segura, Cecilia del Carmen (Hospital Universitari Vall d'Hebron) ; Yeh, Su-Peng (China Medical University Hospital) ; Bouabdallah, Krimo (University Hospital of Bordeaux) ; Cartron, Guillaume (Centre Hospitalier Universitaire Montpellier) ; Kim, Won Seog (Samsung Medical Center) ; Cordoba, Raul (Hospital Universitario Fundación Jiménez Díaz) ; Koh, Youngil (Seoul National University Hospital) ; Re, Alessandro (ASST Spedali Civili Brescia) ; Alves, Daniela (Centro Hospitalar Universitário Lisboa Norte) ; Chamuleau, Martine (Vrije Universiteit Amsterdam) ; Le Gouill, Steven (Institut Curie) ; López Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ; Moreira, Ilídia (Portuguese Institute of Oncology of Porto) ; van der Poel, Marjolein W. M. (Maastricht University Medical Center) ; Abbadessa, Giovanni (Sanofi) ; Meng, Robin (Sanofi) ; Ji, Ran (Sanofi) ; Lépine, Lucie (Sanofi) ; Saleem, Rao (Sanofi) ; Ribrag, Vincent (Institut Gustave Roussy (Villejuif, França)) ; Universitat Autònoma de Barcelona
Patients with relapsed or refractory lymphoma have limited treatment options, requiring newer regimens. In this Phase 1/2 study (NCT03769181), we assessed the safety, efficacy, and pharmacokinetics of isatuximab (Isa, anti-CD38 antibody) in combination with cemiplimab (Cemi, anti-programmed death-1 [PD-1] receptor antibody; Isa + Cemi) in patients with classic Hodgkin lymphoma (cHL), diffuse large B-cell lymphoma (DLBCL), and peripheral T-cell lymphoma (PTCL). [...]
2022 - 10.1002/hon.3089
Hematological Oncology, Vol. 41 (october 2022) , p. 108-119  
Registre complet - Creative Commons
3.
13 p, 463.3 KB Targeting CD19 in diffuse large B-cell lymphoma : An expert opinion paper / Bailly, Sarah (Département d'Hématologie. Cliniques Universitaires Saint-Luc) ; Cartron, Guillaume (Centre Hospitalier Universitaire de Montpellier) ; Chaganti, Sridhar ; Cordoba, Raul (Hospital Universitario Fundación Jiménez Díaz) ; Corradini, Paolo (University of Milan) ; Düll, Johannes (Medizinische Klinik und Poliklinik II. Universitätsklinikum Würzburg) ; Ferrarini, Isacco (Department of Medicine. Section of Hematology. University of Verona) ; Osborne, Wendy (Newcastle Upon Tyne Hospitals NHS Foundation Trust) ; Rosenwald, Andreas (University of Würzburg) ; Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Tilly, Hervé (Centre Henri Becquerel and University of Rouen) ; Van Den Neste, Eric (Cliniques Universitaires Saint-Luc) ; Viardot, Aandreas (University Hospital of Ulm (Alemanya)) ; Visco, Carlo (University of Verona) ; Universitat Autònoma de Barcelona
The ubiquitous, early-stage expression, efficient internalization, limited off-target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti-CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. [...]
2022 - 10.1002/hon.3013
Hematological Oncology, Vol. 40 Núm. 4 (october 2022) , p. 505-517  
Registre complet - Creative Commons
4.
7 p, 812.6 KB Genetics and epigenetics of leukemia and lymphoma : from knowledge to applications, meeting report of the Josep Carreras Leukaemia Research Institute / Parra, Maribel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Baptista, Maria Joao (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Genescà, Eulàlia (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Llinàs-Arias, Pere (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Esteller, M. (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Universitat Autònoma de Barcelona
The meeting, which brought together leading scientists and clinicians in the field of leukemia and lymphoma, was held at the new headquarters of the Josep Carreras Leukaemia Research Institute (IJC) in Badalona, Catalonia, Spain, September 19-20, 2019. [...]
2020 - 10.1002/hon.2725
Hematological Oncology, Vol. 38 Núm. 4 (january 2020) , p. 432-438  
Registre complet - Creative Commons

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.
Dipòsit Digital de Documents de la UAB :: Cerca :: Lliura :: Personalitza :: Ajuda
Powered by Invenio v1.1.6
Mantingut per ddd.bib@uab.cat  :: Metadades subjectes a:
Col·laborem